(MVA), has been used to develop vaccine candidates against Crimean-Congo Haemorrhagic Fever (CCHF) virus through incorporation of the nucleoprotein (NP) and glycoprotein (GP) regions, with the former candidate having now progressed to being the first vaccine against CCHF virus to enter Phase 1 ...
H1N1 virus: A plan for the worst And although the H1N1 virus seems to have lost some of its virulent momentum, the pandemic potential should give employers the impetus to put together a … http://www.canadianbusiness.com/managing/strategy/article.jsp?content=20090615_10014_10014 May 26, 2009...